# Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)

> **NCT07319910** · — · TEMPORARILY_NOT_AVAILABLE · sponsor: **NovoCure GmbH**

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **DEVICE:** TTFields
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT07319910
- **Lead sponsor:** NovoCure GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** TEMPORARILY_NOT_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07319910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07319910, "Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07319910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*